Filing Analysis
Daré Bioscience, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing is a standard earnings release notification and does not contain substantive new material agreements or structural changes.
📋 Key Facts
- Company announced financial results for the quarter ended June 30, 2026.
- Filing date: August 13, 2026.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Dare Bioscience, Inc. filed an 8-K to furnish a corporate presentation dated July 24, 2026, intended for use in meetings with securities market participants.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- A corporate presentation was furnished as Exhibit 99.1 on July 24, 2026.
- The company intends to use the presentation in various meetings with market participants starting July 24, 2026.
Dare Bioscience, Inc. received a notice from Nasdaq stating it is in non-compliance with Listing Rule 5550(b) due to insufficient stockholders' equity and failure to meet alternative listing requirements. The company intends to request a hearing to stay the delisting process.
🚩 Red Flags
- Delisting notice from Nasdaq
- Extremely low stockholders' equity (<$2.5M)
- Failure to meet alternative market value or net income requirements
- High risk of losing exchange listing
📋 Key Facts
- Nasdaq notified the company on July 13, 2026, of non-compliance with Listing Rule 5550(b).
- The deficiency is driven by stockholders' equity being less than $2.5 million as of March 31, 2026.
- The company failed to meet alternative requirements: $35 million in market value or $500,000 in net income from continuing operations.
- The company intends to request a hearing before a Nasdaq Hearing Panel to stay the delisting.
Dare Bioscience, Inc. filed an 8-K to furnish a corporate presentation dated July 13, 2026, under Item 7.01 (Regulation FD Disclosure). The filing is intended for use in meetings with securities market participants.
📋 Key Facts
- The company furnished a corporate presentation as Exhibit 99.1.
- The presentation is dated July 13, 2026.
- Information was provided under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Dare Bioscience, Inc. filed an 8-K to furnish a corporate presentation dated June 22, 2026, intended for use in meetings with securities market participants.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- A corporate presentation was furnished as Exhibit 99.1.
- The company intends to make the presentation available on its investor relations website.
Daré Bioscience reported the results of its 2026 annual meeting of stockholders held on June 11, 2026. Key approvals include an increase in shares for the 2022 Stock Incentive Plan and the authorization of future share issuances under an existing equity line with Lincoln Park Capital Fund, LLC.
🚩 Red Flags
- Approval of shares for an equity line with Lincoln Park Capital Fund, LLC often indicates a reliance on 'at-the-market' or similar dilutive financing strategies common in micro-cap companies to sustain operations.
📋 Key Facts
- Stockholders approved an amendment to the 2022 Stock Incentive Plan to increase available shares by 1,500,000.
- Stockholders approved the potential future issuance of common stock under an existing equity line with Lincoln Park Capital Fund, LLC (Proposal 5).
- Gregory W. Matz and Sabrina Martucci Johnson were elected as Class III directors.
- Haskell & White LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- The board determined to hold advisory votes on executive compensation annually.
Daré Bioscience completed a closing of its Regulation A offering on May 14, 2026, issuing 50,000 Investor Units at $5.00 per unit. Each unit consists of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock.
🚩 Red Flags
- Dilutive financing structure involving convertible preferred stock and warrants.
- Relatively small capital raise ($250,000) in this closing may indicate a high frequency of incremental funding needs.
📋 Key Facts
- Closing occurred on May 14, 2026.
- Issued 50,000 Investor Units at a price of $5.00 per unit, totaling $250,000 in gross proceeds for this closing.
- Each unit includes one share of Series A Convertible Preferred Stock and two warrants (100,000 warrants total).
- The offering is conducted under Regulation A pursuant to an offering statement on Form 1-A qualified on April 1, 2026.
- The total offering allows for up to 4,854,000 units.
Daré Bioscience, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release furnished with the SEC. The filing serves as a routine quarterly update on the company's financial condition and results of operations.
📋 Key Facts
- The report covers the fiscal quarter ended March 31, 2026.
- The company furnished the information under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results was included as Exhibit 99.1.
- The filing was signed by Sabrina Martucci Johnson, President and CEO.
Daré Bioscience completed multiple closings of a Regulation A offering between May 1 and May 6, 2026, issuing 195,010 Investor Units at $5.00 per unit. The offering raised approximately $975,050 in gross proceeds and involves the issuance of convertible preferred stock and warrants.
🚩 Red Flags
- Potential for significant dilution due to the issuance of convertible preferred stock and double warrants (two warrants per unit).
- Reliance on Regulation A offerings, which are often utilized by micro-cap companies when traditional institutional capital markets are less accessible.
📋 Key Facts
- Closings occurred on May 1, 4, 5, and 6, 2026.
- Issued 195,010 Investor Units, each consisting of one share of Series A Convertible Preferred Stock and two warrants.
- The offering price was $5.00 per Investor Unit.
- A total of 390,020 warrants were issued in connection with these closings.
- The offering is conducted under Regulation A pursuant to an offering statement on Form 1-A qualified on April 1, 2026.
Daré Bioscience updated its corporate presentation on April 22, 2026, and made it available on its investor relations website. The presentation was furnished as an exhibit to provide current information to investors under Regulation FD.
📋 Key Facts
- Updated corporate presentation made available on April 22, 2026
- Information furnished under Item 7.01 Regulation FD Disclosure
- Exhibit 99.1 contains the full presentation dated April 22, 2026
Daré Bioscience completed a closing of its Regulation A offering on April 17, 2026, issuing 20,000 Investor Units at $5.00 per unit. Each unit includes one share of Series A Convertible Preferred Stock and two warrants for common stock.
🚩 Red Flags
- Potential for significant dilution from convertible preferred stock and warrants.
- The current closing raised only $100,000, a very small fraction of the $24.27 million maximum offering capacity.
- Reliance on Regulation A offerings often indicates a company is targeting retail investors because institutional capital is less accessible.
📋 Key Facts
- Issued 20,000 Investor Units for total gross proceeds of $100,000 on April 17, 2026.
- Each unit consists of one Series A Convertible Preferred share and two warrants to purchase common stock.
- The offering is part of a larger Regulation A program for up to 4,854,000 units (potential $24.27 million).
- The offering statement was qualified by the SEC on April 1, 2026.
Daré Bioscience rebalanced its staggered Board of Directors by moving Gregory W. Matz from Class II to Class III. This administrative change involved a technical resignation and immediate reappointment to ensure even distribution across board classes.
📋 Key Facts
- The Board of Directors consists of six members divided into three classes.
- Gregory W. Matz resigned as a Class II director on April 16, 2026.
- Mr. Matz was simultaneously reappointed as a Class III director.
- The reclassification was performed to rebalance the board so each class consists of approximately one-third of the total directors.
- Mr. Matz will now stand for re-election at the 2026 annual meeting of stockholders instead of 2028.
Daré Bioscience completed a closing of its Regulation A offering on April 10, 2026, issuing 3,470 Investor Units at $5.00 per unit. Each unit consists of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock.
🚩 Red Flags
- The issuance of convertible preferred stock and warrants is dilutive to existing common stockholders.
- The extremely small size of this specific closing ($17,350) may indicate weak investor demand for the Regulation A offering.
📋 Key Facts
- Completed a closing of a Regulation A offering on April 10, 2026.
- Issued 3,470 Investor Units at a price of $5.00 per unit, totaling $17,350 in this specific closing.
- Each unit includes one share of Series A Convertible Preferred Stock and two warrants (6,940 warrants total).
- The offering is conducted under Form 1-A (File No. 024-12688), qualified by the SEC on April 1, 2026.
- The total offering size is up to 4,854,000 units.
Daré Bioscience, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release furnished on March 26, 2026.
📋 Key Facts
- Financial results for the year ended December 31, 2025 were announced.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release was included as Exhibit 99.1.
- The filing was signed by CEO Sabrina Martucci Johnson.
Daré Bioscience completed a closing of its Regulation A offering on March 16, 2026, issuing 43,050 units at $5.00 per unit. Each unit consists of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock.
🚩 Red Flags
- Dilutive financing structure involving convertible preferred stock and warrants
- Low capital intake in this specific closing ($215,250) relative to the $24.27M offering maximum
📋 Key Facts
- Closed a portion of a Regulation A offering on March 16, 2026
- Issued 43,050 Investor Units at a price of $5.00 per unit
- Gross proceeds from this specific closing totaled approximately $215,250
- Each unit contains one share of Series A Convertible Preferred Stock and two warrants (86,100 warrants total in this closing)
- The total offering is for up to 4,854,000 units (approximately $24.27 million maximum)
- The offering statement on Form 1-A was qualified by the SEC on January 5, 2026
Daré Bioscience completed the second closing of its Regulation A offering on March 6, 2026, raising approximately $87,500. The company issued 17,500 units, each consisting of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock.
📋 Key Facts
- Closing date: March 6, 2026
- Units issued in this closing: 17,500
- Offering price: $5.00 per unit
- Total warrants issued in this closing: 35,000
- The offering is part of a larger Regulation A offering of up to 4,854,000 units
- Each unit contains one share of Series A Convertible Preferred Stock and two warrants
Daré Bioscience, Inc. updated its corporate presentation on March 2, 2026, and made it available on its investor relations website. The presentation is furnished as an exhibit to the 8-K filing under Regulation FD.
📋 Key Facts
- Updated corporate presentation released on March 2, 2026.
- Presentation is available on the company's website at https://ir.darebioscience.com.
- The filing is furnished under Item 7.01 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Daré Bioscience has initiated a Regulation A offering of up to 4,854,000 Investor Units consisting of Series A Convertible Preferred Stock and warrants. The filing includes the establishment of new Series A Preferred Stock with specific conversion and redemption terms designed to raise capital.
🚩 Red Flags
- Significant dilution potential: The conversion price of $2.50 is significantly higher than the recent closing price of $1.90, but the warrants and preferred stock structure create substantial overhang.
- Complex capital structure: Use of Series A Preferred with liquidation preferences and call options adds complexity to the cap table.
- High selling agent fees: 7.25% placement fee plus additional consulting/expense reimbursements.
📋 Key Facts
- Offering size: Up to 4,854,000 Investor Units (each unit = 1 share of Series A Preferred + 2 warrants).
- Offering price: $5.00 per unit.
- Series A Preferred Stock terms: $5.00 liquidation preference; no voting rights; no dividends.
- Conversion feature: Initial conversion price of $2.50 per share (initially convertible into two shares of Common Stock).
- Warrant terms: Investor Warrants have an exercise price of $4.00 for 36 months.
- Company Call Option: Company can redeem Series A Preferred at the lesser of stated value + 8% annual return or 200% of stated value after 3 years.
- Forced Conversion: Triggered by change in control, common stock price $\ge$ $4.50 for 10/30 days, or a firm commitment public offering $\ge$ $15M at $\ge$ $4.50/share.
Daré Bioscience, Inc. has released an updated corporate presentation via its investor relations website as of January 6, 2026.
📋 Key Facts
- The company furnished an updated corporate presentation dated January 6, 2026, as Exhibit 99.1.
- Information was made available in the 'Investors' section of the company website (https://ir.darebioscience.com).
- The disclosure is being furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Bayer HealthCare LLC has issued a notice to terminate its license agreement with Daré Bioscience regarding the development and commercialization of Ovaprene in the U.S., effective February 24, 2026. The termination is due to Bayer's strategic prioritization and will result in the loss of future milestone payments and expert support from Bayer.
🚩 Red Flags
- Loss of a major strategic partner (Bayer) and associated milestone/royalty revenue streams.
- Loss of expert support for clinical, regulatory, and manufacturing activities previously provided by Bayer.
- Increased reliance on remaining grant funding to maintain clinical trial recruitment.
📋 Key Facts
- Bayer terminated the license agreement dated January 10, 2020.
- Termination effective date: February 24, 2026 (90 days from notice).
- Daré will lose all future license fees, milestone payments, and expert support from Bayer.
- A $1.0 million upfront non-refundable fee previously received will be recorded as revenue upon termination.
- The company expects no material impact on the ongoing Phase 3 clinical study of Ovaprene.
- Enrollment for the Phase 3 study is anticipated to complete in 2026, supported by November 2024 grant funding.
Dare Bioscience, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal notification that earnings data has been released via press release.
📋 Key Facts
- The company issued a press release on November 13, 2025, regarding quarterly financial results.
- Reporting period: Quarter ended September 30, 2025.
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Dare Bioscience, Inc. filed an 8-K to provide a corporate presentation under Regulation FD. The filing is intended for use in meetings with securities market participants and on the company's investor relations website.
📋 Key Facts
- The filing includes Exhibit 99.1, which is a corporate presentation dated September 2, 2025.
- The information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
- The company intends to use this presentation in various meetings with market participants starting September 2, 2025.
Dare Bioscience, Inc. issued an 8-K to announce its financial results for the quarterly period ended June 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting date: August 14, 2025.
- Period covered: Quarter ended June 30, 2025.
Daré Bioscience has received confirmation from Nasdaq that it is currently in compliance with the Stockholders' Equity Rule. However, the company has been placed under a Mandatory Panel Monitor for one year due to previous non-compliance.
🚩 Red Flags
- Mandatory Panel Monitor status indicates recent/previous failure to meet minimum equity requirements.
- Loss of standard cure rights: If non-compliance recurs during the one-year monitor period, the company cannot submit a plan of compliance or seek additional time before delisting.
📋 Key Facts
- Nasdaq confirmed compliance with Nasdaq Listing Rule 5550(b)(1) (Stockholders’ Equity Rule) as of July 24, 2025.
- The company is subject to a Mandatory Panel Monitor for one year starting July 24, 2025.
- Under the monitor period, if compliance is lost, Nasdaq will issue an immediate delist determination without allowing a plan of compliance or additional cure periods.
Daré Bioscience reports that recent ATM equity offerings have raised gross proceeds of $16.5 million, bringing stockholders' equity above the $2.5 million Nasdaq minimum requirement. The company intends to notify Nasdaq to seek a determination regarding regained compliance with listing rules.
🚩 Red Flags
- History of non-compliance with Nasdaq listing rules since August 2024.
- Reliance on dilutive ATM (at-the-market) equity offerings to meet minimum capital requirements.
- Uncertainty regarding whether Nasdaq will officially grant compliance status.
📋 Key Facts
- Gross proceeds from ATM and equity line sales: ~$16.5 million (from March 31, 2025, to July 18, 2025).
- Total shares outstanding after recent sales: approximately 12.6 million.
- The company was out of compliance with Nasdaq Listing Rule 5550(b) since August 2024.
- Stockholders' equity is now believed to be in excess of the $2.5 million minimum required under Nasdaq Listing Rule 5550(b)(1).
Dare Bioscience released interim Phase 3 clinical trial data for its investigational contraceptive, Ovaprene®. The Data Safety Monitoring Board recommended the study continue without modification following a safety review.
🚩 Red Flags
- 17% discontinuation rate due to vaginal odor, which may impact long-term product acceptability/compliance.
📋 Key Facts
- Interim analysis conducted on July 11, 2025, by a Data Safety Monitoring Board (DSMB).
- The DSMB recommended the Ovaprene Phase 3 study continue without modification.
- No new safety or tolerability concerns were identified during the interim review.
- Approximately 9% of treated women had experienced pregnancy at the time of analysis.
- 17% of participants discontinued due to vaginal odor, cited as the most common product-related adverse event.
- Target enrollment for the study is approximately 250 participants; ~115 have completed or are ongoing.
- The primary objective is to assess the Pearl Index (pregnancy rate) over 13 menstrual cycles.
Dare Bioscience, Inc. reported the results of its reconvened annual meeting of stockholders held on July 9, 2025. Stockholders approved an amendment to the 2022 Stock Incentive Plan and ratified several director elections and auditor appointments.
🚩 Red Flags
- Meeting required reconvening due to lack of quorum at the initial June 12 meeting (indicates potential shareholder apathy or engagement issues).
📋 Key Facts
- Stockholders approved an amendment to the 2022 Stock Incentive Plan, increasing available shares by 600,000.
- Three Class II directors (Gregory W. Matz, William H. Rastetter, and Robin J. Steele) were elected to terms ending in 2028.
- Haskell & White LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- Stockholders approved executive compensation on an advisory basis (Say-on-Pay).
- The meeting was reconvened on July 9, 2025, after a previous attempt on June 12, 2025, failed to reach a quorum.
Nasdaq has approved Daré Bioscience's modified multi-step plan to regain compliance with listing rules, but the company remains under a conditional continued listing period ending August 12, 2025. The company must demonstrate compliance with either stockholders' equity or minimum market value requirements by July 31, 2025.
🚩 Red Flags
- Imminent delisting risk with a hard deadline of August 12, 2025.
- Ongoing non-compliance since August 2024 (nearly one year).
- High uncertainty regarding the ability to execute the plan or raise sufficient capital by the July 31 milestone.
📋 Key Facts
- Nasdaq Hearings Panel approved a modified multi-step plan to demonstrate compliance with Listing Rule 5550(b).
- The conditional continued listing period expires on August 12, 2025.
- Compliance must be demonstrated by July 31, 2025, regarding either the Stockholders' Equity Rule ($2.5M minimum) or the Minimum MVLS Rule ($35.0M minimum).
- The company has been non-compliant with Nasdaq Listing Rule 5550(b) since August 2024.
- If compliance is met via the Minimum MVLS Rule, the company must disclose transactions used to increase equity and provide updated income projections.
Dare Bioscience, Inc. filed an 8-K to provide a corporate presentation dated June 9, 2025, pursuant to Regulation FD Disclosure. This filing is intended for use in meetings with securities market participants and on the company's investor relations website.
📋 Key Facts
- The filing contains a corporate presentation (Exhibit 99.1) dated June 9, 2025.
- The information is being furnished under Item 7.01 (Regulation FD Disclosure).
- The company intends to use the presentation in meetings with securities market participants starting June 9, 2025.
Dare Bioscience, Inc. filed an 8-K to announce its quarterly financial results for the period ending March 31, 2025. The filing serves as a formal notice that a press release containing these results has been issued.
📋 Key Facts
- The company announced financial results for the quarter ended March 31, 2025.
- Results were released via press release on May 13, 2025.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
Nasdaq has granted Daré Bioscience an extension until August 12, 2025, to demonstrate compliance with minimum stockholders' equity or market value requirements. The company is currently non-compliant and must meet specific capital raising milestones by April 30 and July 15, 2025, to avoid delisting.
🚩 Red Flags
- Ongoing non-compliance with Nasdaq listing rules since August 2024.
- High dependency on successful capital raising activities by strict deadlines (April 30 and July 15) to avoid delisting.
- Risk of immediate delisting action after April 30, 2025, if the Panel is dissatisfied with progress.
📋 Key Facts
- Nasdaq Hearings Panel granted an extension until August 12, 2025, to demonstrate compliance with Nasdaq Listing Rule 5550(b).
- Compliance requires meeting either the Stockholders' Equity Rule ($2.5 million minimum) or the Minimum MVLS Rule ($35.0 million minimum market value of listed securities).
- The company has been non-compliant since August 2024.
- A multi-step plan is in place to increase stockholders' equity by April 30, 2025, and again by July 15, 2025.
- Failure to execute the plan or meet milestones may result in delisting after April 30, 2025.
Dare Bioscience, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal notice that a press release containing these results was issued on March 31, 2025.
📋 Key Facts
- The company released its full-year financial results for the period ending December 31, 2024.
- Results were announced via press release on March 31, 2025.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
Dare Bioscience, Inc. has been notified by Nasdaq that its common stock is subject to delisting because it failed to regain compliance with the Minimum Market Value of Listed Securities (MVLS) Rule by the February 10, 2025 deadline.
🚩 Red Flags
- Failure to meet minimum market value requirements for continued listing.
- Imminent risk of delisting from the Nasdaq Capital Market.
- Uncertainty regarding whether a Nasdaq Hearing Panel will grant an extension or maintain the listing.
📋 Key Facts
- Nasdaq issued a notice on February 13, 2025, stating the company is subject to delisting.
- The company failed to meet Nasdaq Listing Rule 5550(b)(2), which requires a minimum market value of listed securities of $35.0 million.
- The initial 180-day compliance period expired on February 10, 2025.
- The Company intends to request a hearing before the Nasdaq Hearing Panel to stay the delisting process.
Dare Bioscience, Inc. filed an 8-K to provide a corporate presentation for use at the BIO CEO & Investor Conference on February 10, 2025. The filing is made pursuant to Regulation FD disclosure requirements.
📋 Key Facts
- The company released a new corporate presentation dated February 10, 2025.
- The presentation was prepared for use at the BIO CEO & Investor Conference in New York, NY.
- Information is being furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Dare Bioscience, Inc. filed an 8-K to provide a corporate presentation dated January 13, 2025, as part of its Regulation FD disclosures. The filing is intended for use in meetings with securities market participants and on the company's investor relations website.
📋 Key Facts
- The filing includes a corporate presentation (Exhibit 99.1) dated January 13, 2025.
- Information is being furnished under Item 7.01 (Regulation FD Disclosure).
- The company intends to use the presentation in meetings with market participants starting January 13, 2025.
Daré Bioscience announced clinical development plans for Sildenafil Cream (for female sexual arousal disorder) following FDA discussions. The company intends to submit a Phase 3 study protocol in Q1 2025 and aims to start the trial in mid-2025.
🚩 Red Flags
- Forward-looking statements highlight significant risk regarding the potential insufficiency of capital resources to advance development.
- Risk that Phase 3 may fail to demonstrate statistically significant differences in efficacy despite successful Phase 2b results.
- Requirement for a second confirmatory Phase 3 study increases total capital requirement and time to market.
📋 Key Facts
- Planned submission of Phase 3 clinical study protocol/statistical analysis plan to the FDA in Q1 2025.
- Targeting mid-2025 for commencement of the first Phase 3 study for Sildenafil Cream.
- Phase 3 design will include a 12-week double-blind treatment period comparing cream to placebo.
- Co-primary efficacy endpoints: arousal sensations and associated distress.
- A second confirmatory Phase 3 study will be required for NDA submission.
Dare Bioscience, Inc. filed an 8-K to announce its financial results for the quarterly period ended September 30, 2024.
📋 Key Facts
- The filing was made on November 14, 2024.
- The report pertains to Item 2.02: Results of Operations and Financial Condition.
- Financial results for the quarter ended September 30, 2024, were released via press release (Exhibit 99.1).
Dare Bioscience, Inc. filed an 8-K to provide a corporate presentation dated October 25, 2024, intended for use in meetings with investors and analysts.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- A corporate presentation (Exhibit 99.1) was released on October 25, 2024.
- The information in the presentation is being furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Daré Bioscience entered into a subaward agreement with VentureWell (on behalf of ARPA-H) to receive up to $10.0 million in milestone-based funding for its DARE-HPV development program. The funds are intended to support nonclinical studies, FDA IND clearance, and the commencement of Phase 2 clinical trials over a 24-month period.
🚩 Red Flags
- Milestone-based structure: Funding is contingent upon achieving specific research and regulatory objectives (IND clearance, Phase 2 commencement).
- Intellectual Property restrictions: ARPA-H retains nonexclusive license rights and imposes restrictions on the sale or transfer of technology to foreign entities without approval.
- Termination risk: The agreement can be terminated if the Prime Agreement is materially changed or due to performance disputes.
📋 Key Facts
- Total potential award amount: up to $10.0 million in milestone-based payments.
- Funding source: ARPA-H (via VentureWell) under the 'Sprint for Women’s Health' program.
- Performance Period: 24 months from October 23, 2024.
- Milestones include IND-enabling nonclinical studies, FDA IND clearance, and commencement of a Phase 2 clinical study.
- More than 50% of the award is payable within the first 12 months subject to performance.
- The agreement includes 'march-in' rights for ARPA-H and restrictions on foreign access/transfer of technology without prior approval.
Dare Bioscience entered into a purchase agreement with Lincoln Park Capital Fund, LLC for the sale of up to $15.0 million in common stock over a 24-month period. This equity commitment is designed to provide working capital and general corporate purposes through a variable-rate pricing mechanism.
🚩 Red Flags
- Variable-rate pricing mechanism (often results in significant dilution for existing shareholders).
- The use of an equity line of credit/purchase agreement is a common sign of limited access to traditional debt financing.
- Potential for downward pressure on stock price due to the 'lowest closing sale price' pricing formula.
📋 Key Facts
- Entered into a Purchase Agreement and Registration Rights Agreement with Lincoln Park Capital Fund, LLC on October 21, 2024.
- Lincoln Park committed to purchase up to $15.0 million in shares of common stock.
- The agreement has a 24-month term commencing upon the effectiveness of the registration statement.
- Pricing for regular purchases is set at the lower of (i) the current day's sale price or (ii) the average of the three lowest closing prices over the preceding 10 business days.
- The company issued 137,614 shares to Lincoln Park on October 21, 2024, as consideration for the commitment.
- Sales are subject to a Nasdaq Exchange Cap (19.99% of outstanding shares) unless specific price or stockholder approval conditions are met.
Dare Bioscience, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2024.
📋 Key Facts
- The filing was made on August 12, 2024.
- The report pertains to the second quarter (Q2) ended June 30, 2024.
- Financial results were released via a press release attached as Exhibit 99.1.
Daré Bioscience has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, resolving a previous delisting risk. The company is currently focused on progressing its Phase 3 pivotal studies for Sildenafil Cream.
🚩 Red Flags
- Previous history of non-compliance with Nasdaq's $1.00 minimum bid price requirement.
📋 Key Facts
- The Company successfully maintained a closing bid price of $1.00 or greater for ten consecutive trading sessions prior to July 16, 2024.
- Nasdaq Office of General Counsel notified the company on July 18, 2024, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2).
- The matter regarding the minimum bid price requirement is now considered closed by Nasdaq.
- The company is awaiting FDA feedback regarding endpoints and safety database requirements for its Sildenafil Cream Phase 3 studies.
Dare Bioscience, Inc. has announced a 1-for-12 reverse stock split to be effective July 1, 2024. This action will reduce the number of issued and outstanding common shares from approximately 101.1 million to approximately 8.4 million.
🚩 Red Flags
- Reverse stock split (typically used to boost share price to meet exchange listing requirements or improve perception)
- Significant reduction in float/outstanding shares
📋 Key Facts
- Reverse Stock Split Ratio: 1-for-12
- Effective Date: July 1, 2024, at 12:01 a.m. ET
- Trading Adjustment: Expected to begin trading on a split-adjusted basis on Nasdaq Capital Market on July 1, 2024
- Share Count Impact: Reduces outstanding shares from ~101.1 million to ~8.4 million
- CUSIP Change: A new CUSIP number (23666P200) has been assigned
- Fractional Shares: No fractional shares will be issued; interests will be rounded up to the next whole share
- Other Adjustments: Proportional adjustments will be made to exercise prices and share counts for outstanding stock options and warrants
Dare Bioscience, Inc. held its annual meeting of stockholders on June 5, 2024, where shareholders approved a proposal granting the Board discretion to execute a reverse stock split (ratio between 1-for-2 and 1-for-12) prior to June 5, 2025.
🚩 Red Flags
- Approval of a reverse stock split is often used to maintain compliance with exchange listing requirements (Nasdaq), suggesting potential minimum bid price pressure.
- The wide range of the proposed ratio (1-for-2 to 1-for-12) indicates uncertainty regarding the necessary magnitude of the consolidation.
📋 Key Facts
- Annual meeting held on June 5, 2024.
- Proposal 4: Shareholders approved discretionary authority for the Board to effect a reverse stock split with a ratio between 1-for-2 and 1-for-12.
- The reverse split must be completed before June 5, 2025.
- Haskell & White LLP was ratified as the independent registered public accounting firm for FY2024 (Proposal 2).
- Two director nominees (Jessica D. Grossman and Susan L. Kelley) were elected to Class I director positions.
Dare Bioscience, Inc. filed an 8-K to announce its financial results for the quarterly period ended March 31, 2024.
📋 Key Facts
- Report date: May 14, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing is a standard announcement of quarterly results via press release (Exhibit 99.1).
Daré Bioscience entered into two royalty purchase agreements with XOMA (US) LLC, receiving an upfront payment of $22.0 million in exchange for assigning various future royalty streams and milestone payments.
🚩 Red Flags
- Significant monetization of future revenue streams (royalty selling) often indicates a need for immediate liquidity.
- Granting of security interests in core product assets (Ovaprene and Sildenafil Cream) to XOMA.
- Restrictions on the company's ability to incur further indebtedness or liens related to these specific receivables/assets.
📋 Key Facts
- Upfront cash payment: $22.0 million received on April 29, 2024.
- XOMA purchased 100% of royalties/milestones from the Organon License Agreement (XACIATO™) net of certain third-party payments.
- XOMA acquired 25% of a potential $20.0 million milestone payment from Bayer HealthCare LLC related to Ovaprene®.
- Daré granted XOMA a synthetic royalty of 4.0% on future net sales of Ovaprene and 2.0% on Sildenafil Cream (subject to reduction if total payments exceed $110M).
- XOMA holds a security interest in certain product assets related to Ovaprene and Sildenafil Cream.
- Contingent purchase price: XOMA will pay Daré an additional $11.0 million for every $22.0 million received after reaching an $88.0 million threshold.
Dare Bioscience, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023.
📋 Key Facts
- The filing is a standard announcement of annual financial results (Item 2.02).
- Reporting date: March 28, 2024.
- Financial results cover the fiscal year ended December 31, 2023.
Dare Bioscience announced a significant leadership overhaul including the retirement of its CFO, the resignation of its Chief Commercial Officer, and a reduction in Board size. The company is implementing cost-cutting measures by not replacing these executive roles immediately.
🚩 Red Flags
- Multiple officer departures (CFO and CCO) within a short timeframe.
- Significant management restructuring/downsizing as part of cost-cutting efforts.
- CEO assuming the role of Principal Financial Officer, increasing concentration of responsibility.
- Board downsizing which can sometimes signal shifting strategic direction or governance changes.
📋 Key Facts
- CFO Lisa Walters-Hoffert retiring effective Jan 26, 2024; transitioning to a 9-month consulting role at $31,667/month plus health insurance reimbursement.
- CEO Sabrina Martucci Johnson will serve as Principal Financial Officer; MarDee Haring-Layton appointed Chief Accounting Officer and Principal Accounting Officer.
- Chief Commercial Officer John Fair resigning effective June 30, 2024; transitioning to part-time status on April 1, 2024 with a 25% salary reduction.
- Board of Directors reducing size from eight members to six following voluntary resignations of Cheryl R. Blanchard and Sophia Ononye-Onyia.
- Company intends not to hire a new CFO or full-time CCO to reduce long-term costs.
Dare Bioscience has received notice from Nasdaq that its common stock is subject to delisting because it failed to regain compliance with the $1.00 minimum bid price requirement by the January 16, 2024 deadline. The company intends to request a hearing before the Nasdaq Hearing Panel to stay the delisting process.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to meet minimum bid price requirement ($1.00)
- Uncertainty regarding the outcome of the upcoming Nasdaq Hearing Panel decision
📋 Key Facts
- Nasdaq notified the Company on January 17, 2024, that it failed to meet the Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)).
- The company's closing bid price was below $1.00 for 30 consecutive business days.
- The initial 180-day compliance period expired on January 16, 2024.
- The Company will request a hearing before the Nasdaq Hearing Panel to stay delisting.
Dare Bioscience, Inc. filed an 8-K to provide a corporate presentation dated January 8, 2024, intended for use in meetings with investors and analysts.
📋 Key Facts
- The filing includes Exhibit 99.1: Corporate presentation dated January 8, 2024.
- The company intends to use the presentation in various investor and analyst meetings starting January 8, 2024.
- Information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 or liability under Sections 11/12(a)(2) of the Securities Act.